VINC (Vincerx Pharma) Common Stock : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Common Stock?

Vincerx Pharma's quarterly common stock increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

Vincerx Pharma's annual common stock stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) and stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Vincerx Pharma Common Stock Historical Data

The historical data trend for Vincerx Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Common Stock Chart

Vincerx Pharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Vincerx Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial														-	-	-	-	-

Vincerx Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Vincerx Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306

Website

https://www.vincerx.com

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

Executives

Alexander A. Seelenberger	officer: Chief Financial Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi	director, 10 percent owner, officer: Chief Operations Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy	director, 10 percent owner, officer: President and CEO	995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas	officer: See Remarks	180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe	director	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang	officer: Chief Business Officer	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang	officer: Chief Technology Officer	260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens	director	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus	officer: Chief Medical Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd	10 percent owner	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054